VERAXA Biotech (NASDAQ: VRXA) is making significant strides in oncology with a diverse pipeline that includes monoclonal antibodies, bispecific antibody-drug conjugates (ADCs), and T-cell engagers, primarily based on its innovative BiTAC technology. The company aims to develop next-generation, smart cancer therapies targeting solid tumors, promising enhanced precision and safety. Positioned to capitalize on two rapidly expanding sectors in oncology, VERAXA is advancing its proprietary therapeutic formats toward clinical development. For more details, you can visit their website.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.theglobeandmail.com/investing/markets/markets-news/Investor%20Brand%20Network/2500965/why-veraxa-biotech-ag-nasdaq-vrxa-is-one-to-watch/
